Form 4: CervoMed Director Jane Hollingsworth Granted Stock Options Following Board Election

CervoMed Inc. director Jane H. Hollingsworth was granted options to purchase 8,100 shares of common stock at an exercise price of $6.52 per share, vesting monthly over one year, following her election to the board.

Summary

• Jane H. Hollingsworth, a Director of CervoMed Inc. (CRVO), was granted stock options on June 23, 2025.
• The grant was made in connection with her election to the Issuer's board of directors at the 2025 Annual Meeting of Stockholders.
• The option allows her to purchase 8,100 shares of CervoMed's common stock.
• The exercise price for these options is $6.52 per share.
• The options were granted under the Issuer's 2025 Equity Incentive Plan, consistent with the non-employee director compensation policy.
• The shares underlying the award will vest on a monthly basis over a one-year period, in substantially equal 1/12th increments, beginning on June 30, 2025.
• Vesting is contingent upon Ms. Hollingsworth's continued service through the applicable vesting date.
• The options have an expiration date of June 23, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of aligning interests and standard corporate practice, indicating stability in governance. It's not a major market moving event but reflects routine positive operations.

Positives

• The grant aligns the interests of the director with shareholders through equity ownership, promoting long-term value creation.
• This transaction represents a standard compensation practice for non-employee directors, indicating stable and established corporate governance.
• The grant is part of a pre-existing 2025 Equity Incentive Plan and non-employee director compensation policy, suggesting a structured and transparent approach to executive incentives.

Future Outlook

The vesting schedule indicates a commitment to the director's continued service over the next year, aligning her incentives with the company's long-term performance.

Industry Context

This transaction is a routine part of corporate governance and director compensation in publicly traded companies, reflecting standard practices for incentivizing board members through equity awards. It does not provide specific insights into broader industry trends beyond general compensation norms.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Interests are aligned with the director through equity ownership, potentially leading to better long-term decision-making.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Continued monthly vesting of 8,100 stock options over a one-year period, starting June 30, 2025.
• Jane H. Hollingsworth's continued service on the board of directors.

Key Dates

Recommendation

Keywords

CervoMed Inc., CRVO, SEC Form 4, Stock Option Grant, Director Compensation, Equity Incentive Plan, Jane H Hollingsworth, Beneficial Ownership, Corporate Governance